By Gilang Cahya 
A groundbreaking study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center has revealed a significant underestimation of cancer spread in many cases of high-risk, nonmetastatic hormone-sensitive prostate cancer. The findings suggest that nearly half of these patients, when evaluated with advanced prostate-specific membrane antigen-positron emission tomography (PSMA-PET) imaging, actually harbor metastatic disease that was undetectable by conventional imaging methods. This revelation has profound implications for prostate cancer staging, treatment decisions, and ultimately, patient outcomes.
The Power of Advanced Imaging: Redefining Prostate Cancer Staging
The study, meticulously detailed in the latest issue of JAMA Network Open, utilized data from 182 patients with high-risk recurrent prostate cancer who were initially believed to have disease confined to the prostate gland. These patients were candidates for the pivotal EMBARK clinical trial, a trial that had previously demonstrated the efficacy of enzalutamide, a potent hormone therapy, when combined with androgen deprivation therapy (ADT) for improving metastasis-free survival. However, the classification of patients within the EMBARK trial relied on conventional imaging techniques, which, as this new research indicates, may have fallen short in accurately assessing the full extent of the disease.
PSMA-PET imaging represents a significant leap forward in visualizing prostate cancer. Unlike traditional imaging modalities like CT or bone scans, which primarily provide anatomical information, PSMA-PET offers functional insights into the disease. This advanced technique employs minuscule amounts of radioactive tracers that selectively bind to prostate-specific membrane antigen (PSMA), a protein that is highly expressed on prostate cancer cells, even in small or widely dispersed metastases. This binding allows these cancer cells to "light up" on PET scans, making previously invisible disease detectable.
Dr. Jeremie Calais, senior author of the study, director of the Ahmanson Translational Theranostics Division’s clinical research program, and associate professor at the department of molecular and medical pharmacology at the David Geffen School of Medicine at UCLA, emphasized the critical role of this technology. "Our study demonstrates the critical role of PSMA-PET in accurately staging prostate cancer, which can significantly impact treatment decisions and outcomes," Dr. Calais stated. He further elaborated on the limitations of older imaging methods, noting that "traditional imaging may underestimate how far the cancer has spread in many cases."
Challenging Conventional Wisdom: The EMBARK Trial Re-examined
The EMBARK trial, a landmark study initiated in 2013 and concluding its primary analysis around 2018, enrolled a substantial number of patients. Its results, published in The New England Journal of Medicine, showed a significant benefit for men receiving enzalutamide plus ADT compared to placebo plus ADT, delaying the development of metastases. However, the patient selection criteria for EMBARK were based on conventional imaging, which may have inadvertently included patients with microscopic metastatic disease that was not apparent on standard scans.
The UCLA-led study, a post hoc, retrospective cross-sectional analysis, revisited the patient population that would have been eligible for EMBARK. By applying PSMA-PET imaging to these individuals, the researchers aimed to quantify the discrepancy between conventional staging and the more sensitive PSMA-PET staging.
The results were striking: PSMA-PET imaging detected metastatic disease in a remarkable 46% of patients who had previously been classified as nonmetastatic by conventional imaging. Furthermore, the advanced imaging revealed that 24% of these patients had five or more metastatic lesions that had been completely missed by traditional scans.
"We anticipated that PSMA-PET would detect more suspicious findings compared to conventional imaging," admitted Dr. Adrien Holzgreve, a visiting assistant professor at the David Geffen School of Medicine and the first author of the study. "However, it was informative to uncover such a high number of metastatic findings in a well-defined cohort of patients resembling the EMBARK trial population that was supposed to only include those without metastases."
Implications for Treatment Strategies and Future Research
The implications of these findings are far-reaching and necessitate a re-evaluation of current treatment paradigms for high-risk prostate cancer. The discrepancy highlighted by PSMA-PET imaging suggests that a significant proportion of patients deemed to have localized disease may, in fact, be benefiting from systemic therapies earlier than previously understood.
Redefining Treatment Eligibility and Opportunities
The ability of PSMA-PET to identify microscopic metastatic disease opens up new possibilities for treatment. For patients with previously undetected metastases, therapies that were previously reserved for those with overt metastatic disease might now be considered. This includes the potential for targeted radiotherapy, such as PSMA-targeted radioligand therapy (RLT), which has shown promise in treating metastatic prostate cancer. If PSMA-PET can identify these metastases earlier, it may allow for more effective and potentially curative interventions before the disease progresses further.
The study also raises important questions about the integration of advanced imaging technologies into standard clinical care. While the clinical adoption of PSMA-PET has been growing, treatment decisions and clinical trial designs have historically been based on data that did not incorporate this superior imaging capability. The findings strongly advocate for the inclusion of PSMA-PET in the patient selection process for future clinical trials, ensuring that participants accurately represent the intended disease stage.
A Shift Towards Personalized Medicine
This research underscores the growing momentum towards personalized medicine in oncology. By providing a more accurate picture of individual disease extent, PSMA-PET imaging can help tailor treatment strategies to the specific needs of each patient. This could lead to more effective treatment regimens, reduced toxicity by avoiding unnecessary interventions, and ultimately, improved survival rates.
Broader Impact on Clinical Trials and Guidelines
The study’s authors suggest that these findings challenge the interpretation of results from previous major clinical trials, like EMBARK, that relied on conventional imaging. They advocate for the future inclusion of PSMA-PET in patient selection for major industry-sponsored clinical trials. This would ensure that trials are designed with a more accurate understanding of disease burden, leading to more robust and reliable results.
The integration of PSMA-PET into standard diagnostic pathways could also influence the development of updated clinical guidelines for prostate cancer management. As the technology becomes more widely available and its benefits further validated, it is likely to become a cornerstone of accurate staging and treatment planning.
Ongoing Research and Future Directions
UCLA researchers are actively pursuing further investigations to solidify the role of PSMA-PET in prostate cancer management. Their ongoing efforts include:
- Analyzing Follow-up Data: The team is meticulously examining follow-up data from four UCLA clinical trials to ascertain how PSMA-PET findings have influenced treatment decisions and, crucially, patient outcomes over time. This prospective analysis will provide vital information on the long-term impact of this advanced imaging.
- International Collaboration: As part of a large international consortium involving over 6,000 patients, the UCLA team is contributing to research focused on understanding the prognostic value of PSMA-PET. This collaborative effort aims to establish the predictive power of PSMA-PET findings for disease progression and survival.
While the current findings offer compelling evidence for the utility of PSMA-PET, Dr. Calais reiterated the need for continued research. "We have good rationales to assume that it is helpful to primarily rely on PSMA-PET findings," stated Dr. Holzgreve. "But more high-quality prospective data would be needed to claim superiority of PSMA-PET for treatment-guidance in terms of patient outcome. However, we are confident PSMA-PET will continue to advance prostate cancer staging and guide personalized therapies."
The study represents a significant step forward in our understanding of prostate cancer staging and highlights the transformative potential of advanced imaging technologies. As research progresses, PSMA-PET imaging is poised to play an increasingly vital role in ensuring that patients receive the most accurate diagnosis and the most effective, personalized treatment for their disease. The journey from initial diagnosis to optimal treatment is being fundamentally reshaped by these evolving diagnostic capabilities, offering renewed hope for improved outcomes in the fight against prostate cancer.
